Reviewer’s report

Title: Safety and Efficacy of Prophylaxis for Pneumocystis jirovecii Pneumonia involving Trimethoprim-Sulfamethoxazole Dose Reduction in Kidney Transplantation

Version: 1 Date: 03 Nov 2018

Reviewer: Alexandre Alanio

Reviewer's report:

Major comments:

The paper should focus on the main message: prophylaxis and reduced dosage.

The cause of dose reduction is somehow out of context. All the results on hypokaliemia and leukopenia should be published apart as a short communication.

The main message here is that dosage reduction of TMP-SMX should be efficient enough to prevent PCP in SOT.

Table 2 and 3 does not add any specific information regarding the main purpose of this study (reduced dose and PcP prophylaxis). I would recommend to deleted them.

Figure 1 is nice. In addition, it should be interesting to create 2 groups within the reduced dose category (twice or thrice weekly?), and compare the characteristics of the patients.

ECIL5 guidelines should be quoted in the introduction even if those recommendations have been built for hematology patients as mainly based on study in non-hematology patients. PMID 27550992.

Minor comment:

PJP should be replaced by PcP (Pneumocystis Pneumonia)
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal